NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Natural History Study of GATA2 Deficiency and Related Disorders

Recruiting

Conditions: GATA2 Deficiency

First Posted Date: 2013-07-23

Last Posted Date: 2025-06-05

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 600

Registration Number: NCT01905826

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Peanut Epicutaneous Phase II Immunotherapy Clinical Trial

Phase 2

Completed

Conditions: Hypersensitivity
Peanut Hypersensitivity
Hypersensitivity, Immediate
Food Hypersensitivity

Interventions: Biological: Placebo Viaskin® Patch
Biological: High-dose DBV712 Viaskin® Patch
Biological: Low-dose DBV712 Viaskin® Patch

First Posted Date: 2013-07-22

Last Posted Date: 2019-07-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 75

Registration Number: NCT01904604

Locations: 🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸
National Jewish Health, Denver, Colorado, United States
🇺🇸
The Johns Hopkins University, Baltimore, Maryland, United States

and more 2 locations

Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in Infants and Children

Phase 1

Active, not recruiting

Conditions: Respiratory Syncytial Virus Infections

Interventions: Biological: Placebo
Biological: RSV ΔNS2 Δ1313 I1314L Vaccine

First Posted Date: 2013-07-09

Last Posted Date: 2023-11-13

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 88

Registration Number: NCT01893554

Locations: 🇺🇸
Center for Immunization Research (CIR), Baltimore, Maryland, United States
🇺🇸
Center for Immunization Research South, Laurel, Maryland, United States

Study of A Combination Pill With GS-7977 and GS-5885 for Hepatitis C in People With HIV

Phase 2

Completed

Conditions: HIV
Hepatitis C

Interventions: Drug: GS-7977/GS- 5885 FDC

First Posted Date: 2013-06-17

Last Posted Date: 2016-09-15

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 50

Registration Number: NCT01878799

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Effects of SQ109 on QTc Interval in Healthy Subjects

Phase 1

Withdrawn

Conditions: Tuberculosis

Interventions: Drug: SQ109
Drug: Moxifloxacin
Other: SQ109 Placebo

First Posted Date: 2013-06-11

Last Posted Date: 2014-03-24

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Registration Number: NCT01874314

Locations: 🇺🇸
Case Western Reserve University - Case Medical Center - Infectious Disease & HIV Medicine, Cleveland, Ohio, United States

Testing Pfs25-EPA/Alhydrogel as a Potential Malaria Transmission Blocking Vaccine

Phase 1

Completed

Conditions: Malaria

Interventions: Biological: Pfs25-EPA/Alhydrogel
Biological: Euvax B
Biological: Menactra

First Posted Date: 2013-06-04

Last Posted Date: 2018-07-05

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 230

Registration Number: NCT01867463

Locations: 🇲🇱
Malaria Research and Training Center, Bamako, Mali

Peanut Oral Immunotherapy in Children

Phase 2

Completed

Conditions: Peanut Hypersensitivity

Interventions: Biological: Peanut Oral Immunotherapy - Liquid Extract
Biological: Placebo for Peanut Oral Immunotherapy - Liquid Extract form
Biological: Peanut Oral Immunotherapy - Peanut Flour
Biological: Placebo for Peanut Oral Immunotherapy - Peanut Flour

First Posted Date: 2013-06-04

Last Posted Date: 2020-03-16

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 146

Registration Number: NCT01867671

Locations: 🇺🇸
UNC Chapel-Hill, Chapel Hill, North Carolina, United States
🇺🇸
Mount Sinai School of Medicine, New York, New York, United States
🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States

and more 2 locations

Challenge Model for Assessment of Human TB Immunity

Phase 1

Completed

Conditions: Tuberculosis

Interventions: Biological: BCG TICE strain

First Posted Date: 2013-06-04

Last Posted Date: 2020-01-27

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 92

Registration Number: NCT01868464

Locations: 🇺🇸
Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States
🇺🇸
Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States

Aerosolized and Intravenous Colistin in Healthy Adults

Phase 1

Terminated

Conditions: Pneumococcal Infection
Pneumonia
Pathogen Resistance

Interventions: Drug: Colistimethate sodium

First Posted Date: 2013-05-29

Last Posted Date: 2020-03-02

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 27

Registration Number: NCT01863719

Locations: 🇺🇸
Johns Hopkins Bayview Medical Center - Infectious Diseases, Baltimore, Maryland, United States
🇺🇸
Case Western Reserve University - Case Medical Center - Infectious Disease & HIV Medicine, Cleveland, Ohio, United States

Collection of Biological Material From Pregnant Women in a Malarial Region

Terminated

Conditions: Malaria

First Posted Date: 2013-05-24

Last Posted Date: 2019-11-25

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 1270

Registration Number: NCT01862783

Locations: 🇺🇬
Kalisizo Hospital, Rakai District, Uganda

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy